

**ZOONO GROUP LIMITED
(ASX: ZNO)**

**ASX ANNOUNCEMENT - 7 July 2026
Quarterly Report and Company Update**

Cash receipts of NZ\$975K for the Quarter (up NZ\$472K and 94%) and Cash Flow Positive of NZ\$55K (an increase of NZ\$238K)

Zoono Group Limited (**Company**) (ASX: ZNO) today releases its Appendix 4C for the quarter ending 30 June 2026. In conjunction with that release, Zoono provides the following quarterly activities report to update shareholders and the market on developments during the quarter and the Company's outlook.

Together with its strategic partner OSY Group Limited (**OSY**), the Company has continued to make significant progress commercialising its shelf-life extension products and technologies across multiple geographies and produce categories.

Shelf-life extension project

United Kingdom

Significant progress has been achieved during the quarter in the UK market. The first material commercial orders under the exclusive soft fruits contract with the UK's leading packaging company have been received, with further orders planned during the next quarter as production scales. Final-stage trials are now in progress with multiple leading UK retailers across the soft fruits category, with commercial rollout expected to follow trial completion.

South Africa

The Company's exclusive agreement with South Africa's leading producer of large-format corrugated packaging is progressing to plan, with the first three quarterly orders placed and a consistent recurring purchasing profile being established. The Company is hopeful of further expansion of its sales into South Africa flowing from:

- a store-based final-stage commercial trial on tomato board punnets initiated with a leading South African retailer; and
- two successful trial programmes with leading South African grape producers (with this initiative leading to advanced negotiations alongside a leading plastic packaging manufacturer for commercial rollout across the upcoming season).

Australia

Trial programmes are now underway on soft fruits with key suppliers to the major Australian food retailers. The Company's exclusive agreement with its Australian plastic packaging

partner underpins these trial programmes, with parallel discussions in progress with leading board-based packaging manufacturers of both small-format and large-format applications. This twin-track approach reflects the breadth of opportunity in the Australian market across multiple packaging formats.

Europe and the Americas

Multiple trials are underway with multinational, multi-produce food producers across Europe and the Americas. The Company is also exploring further partnership and commercial opportunities in the European Union and other key target geographies in the Americas, Africa and Asia, reflecting the global applicability of the Company's technology.

Demonstrated Breadth of Application

Over the past 18 months, the Company has successfully completed a range of trials with commercial partners across a broad set of produce categories, demonstrating both the scope of application and the unique characteristics of the Zoono–OSY solution. It is the Company's intention to expand commercial rollouts into alternative produce categories alongside its packaging partners and directly with end-user customers as the platform matures.

Shipping Containers

Through OSY, and following successful commercial trials in 2025, Zoono products are now being used for the treatment of shipping containers carrying fresh produce from South Africa and Namibia to international markets. The expansion of this business into other countries and shipping companies represents a new recurring product sales stream for the Company's products.

Adjacent and Linked Revenue Streams

Trial programs are also underway in further adjacent and complementary business lines:

- Cut flowers – application of the Company's products and technology to flower sleeves to reduce wastage in the cut flower supply chain; and
- Synergistic shelf-life applications – combining the use of the Company's products with other complementary shelf-life extension technologies.

Outlook

Zoono is confident that it will benefit from materially increased commercial activity over the coming periods from the conclusion of many of its trial programmes, the scaling deliveries under existing exclusive packaging contracts, the expansion of its business collaborations across multiple geographies and packaging formats and, lastly, but equally importantly, the broadening of its business into new application categories.

Summary of Q4 Expenditure

Related party payments of NZ\$114,000 included in the following Appendix 4C were directors' fees (including amounts paid to the executive director) for services rendered.

Expenditure incurred during the quarter on business activities was primarily on staff costs

(NZ\$105K), product manufacturing (NZ\$133K) and administration and corporate overheads (NZ\$677K). Other material expenditure included advertising and marketing (NZ\$33K) and interest and research and development NZ\$11K.

For updates on what is happening globally on a day-to-day basis, follow Zoono

Global on:LinkedIn at: www.linkedin.com/company/zoono/

Instagram: <https://www.instagram.com/zoonoglobal/>

Twitter: <https://twitter.com/zoonoGlobal>

YouTube: <https://www.youtube.com/channel/UCva7oGloBRdAaFnwOzAHjLw>

Newsletters: <https://zoono.co.nz/pages/newsandmedia/>

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

Group MD

M: +64 21 659 977

E: paul.hyslop@zoono.com

Paul Ravlich

Group CFO

M: +64 21 075 9176

E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures, and distributes a suite of scientifically validated, long-lasting and environmentally friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non- toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'Zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi, and mold.

Zoono's products have received numerous regulatory approvals and Zoono's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Zoono Group Limited (ZNO)

ABN

73 006 645 754

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current quarter \$NZ'000	Year to date (12 months) \$NZ'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	972	1,880
1.2	Payments for		
	(a) research and development	-	(5)
	(b) product manufacturing and operating costs	(113)	(355)
	(c) advertising and marketing	(33)	(77)
	(d) leased assets	-	-
	(e) staff costs	(105)	(398)
	(f) administration and corporate costs	(677)	(2,576)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	11	(4)
1.6	Income taxes paid	-	16
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	55	(1,519)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$NZ'000	Year to date (12 months) \$NZ'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	2,046
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(6)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings and leases	(82)	(303)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(82)	1,737

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	307	51
4.2	Net cash from / (used in) operating activities (item 1.9 above)	55	(1,519)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter \$NZ'000	Year to date (12 months) \$NZ'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(82)	1,737
4.5	Effect of movement in exchange rates on cash held	(13)	(2)
4.6	Cash and cash equivalents at end of period	267	267

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$NZ'000	Previous quarter \$NZ'000
5.1	Bank balances	267	307
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	267	307

6.	Payments to related parties of the entity and their associates	Current quarter \$NZ'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	114
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$NZ'000	Amount drawn at quarter end \$NZ'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

--

8.	Estimated cash available for future operating activities	\$NZ'000
8.1	Net cash from / (used in) operating activities (item 1.9)	55
8.2	Cash and cash equivalents at quarter end (item 4.6)	267
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	267
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.85
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 7 July 2026

The Board of Zoono Group Limited

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions

Quarterly cash flow report for entities subject to Listing Rule 4.7B

in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.